MX2022011711A - Compuesto de oxofenilarsina deuterada y uso del mismo. - Google Patents

Compuesto de oxofenilarsina deuterada y uso del mismo.

Info

Publication number
MX2022011711A
MX2022011711A MX2022011711A MX2022011711A MX2022011711A MX 2022011711 A MX2022011711 A MX 2022011711A MX 2022011711 A MX2022011711 A MX 2022011711A MX 2022011711 A MX2022011711 A MX 2022011711A MX 2022011711 A MX2022011711 A MX 2022011711A
Authority
MX
Mexico
Prior art keywords
oxophenylarsine
deuterated
compound
pharmaceutically acceptable
treating
Prior art date
Application number
MX2022011711A
Other languages
English (en)
Inventor
Feng Hong
Fude Huang
Changping Jiao
Wenan Wang
Luxiang Cao
Wanguo Wei
Jiangang Zhang
Original Assignee
Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Tech Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Publication of MX2022011711A publication Critical patent/MX2022011711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)

Abstract

Se da a conocer una oxofenilarsina deuterada, o una sal farmacéuticamente aceptable de la misma, y una composición farmacéutica que contiene un portador farmacéuticamente aceptable y la oxofenilarsina deuterada. La oxofenilarsina deuterada puede usarse para tratar y prevenir cánceres y enfermedades relacionadas.
MX2022011711A 2020-03-31 2021-03-31 Compuesto de oxofenilarsina deuterada y uso del mismo. MX2022011711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010246586 2020-03-31
PCT/CN2021/084773 WO2021197396A1 (zh) 2020-03-31 2021-03-31 氘代氧化苯砷化合物及其应用

Publications (1)

Publication Number Publication Date
MX2022011711A true MX2022011711A (es) 2023-02-14

Family

ID=77927422

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011707A MX2022011707A (es) 2020-03-31 2021-03-31 Aplicaciones de inhibidor de fosfatidilinositol 4-cinasa (pi4k) en enfermedades relacionadas con el plegamineto incorrecto de proteinas intracelulares y enfermedades de almacenamiento lisosomal.
MX2022011711A MX2022011711A (es) 2020-03-31 2021-03-31 Compuesto de oxofenilarsina deuterada y uso del mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022011707A MX2022011707A (es) 2020-03-31 2021-03-31 Aplicaciones de inhibidor de fosfatidilinositol 4-cinasa (pi4k) en enfermedades relacionadas con el plegamineto incorrecto de proteinas intracelulares y enfermedades de almacenamiento lisosomal.

Country Status (13)

Country Link
US (1) US20240050395A1 (es)
EP (2) EP4130014A4 (es)
JP (2) JP2023519424A (es)
KR (2) KR20230020945A (es)
CN (2) CN115515964A (es)
AU (3) AU2021247839A1 (es)
BR (1) BR112022019864A2 (es)
CA (2) CA3171783A1 (es)
CO (1) CO2022015428A2 (es)
IL (1) IL296494A (es)
MX (2) MX2022011707A (es)
PE (1) PE20230042A1 (es)
WO (2) WO2021197389A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3170611A1 (en) * 2020-03-13 2021-09-16 Nuo-Beta Pharmaceutical Technology (Shanghai) Co. Ltd Anti-coronavirus effect and application of pi4k inhibitor
CN118103380A (zh) * 2021-09-30 2024-05-28 挪贝肽医药科技(上海)有限公司 卤代氧化苯砷化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US9421211B2 (en) * 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
EP2723384B1 (en) * 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
AU2013263346B2 (en) * 2012-05-18 2018-08-23 The General Hospital Corporation Methods and compositions for treating amyloid deposits
ES2913526T3 (es) * 2015-04-30 2022-06-02 Jiangsu Nuo Beta Pharmaceutical Tech Co Ltd Método de cribado de fármacos y dianas terapéuticas para el tratamiento de la enfermedad de Alzheimer
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
CN108721622B (zh) * 2017-04-14 2022-10-25 中国科学院上海高等研究院 抑制肝纤维化的试剂及应用
CN109369724B (zh) * 2018-10-23 2021-03-09 兰州大学 一种有机砷化合物及其用途
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用

Also Published As

Publication number Publication date
CA3171783A1 (en) 2021-10-07
AU2021250199A1 (en) 2022-11-03
AU2024203890A1 (en) 2024-06-27
EP4130031A1 (en) 2023-02-08
MX2022011707A (es) 2023-02-14
CO2022015428A2 (es) 2022-11-18
WO2021197389A1 (zh) 2021-10-07
BR112022019864A2 (pt) 2022-11-16
CN115515964A (zh) 2022-12-23
KR20230020946A (ko) 2023-02-13
JP2023519424A (ja) 2023-05-10
AU2021250199B2 (en) 2024-03-07
IL296494A (en) 2022-11-01
AU2021247839A1 (en) 2022-10-13
EP4130014A1 (en) 2023-02-08
EP4130014A4 (en) 2024-05-15
EP4130031A4 (en) 2024-06-26
JP2023520002A (ja) 2023-05-15
CN115515974A (zh) 2022-12-23
WO2021197396A1 (zh) 2021-10-07
PE20230042A1 (es) 2023-01-10
CA3171781A1 (en) 2021-10-07
KR20230020945A (ko) 2023-02-13
US20240050395A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
SG148202A1 (en) Quinazolinone compounds as anticancer agents
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
MX2022011711A (es) Compuesto de oxofenilarsina deuterada y uso del mismo.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2020011453A (es) Combinaciones para tratar el cancer.
ZA202308118B (en) Cdk inhibitor
MX2022009612A (es) Combinacion de bi853520 con farmacos quimioterapeuticos.
MX2021005764A (es) Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).
MX2021012105A (es) Compuestos de pirrol.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
ZA202308282B (en) Toxin molecule suitable for antibody-drug conjugate
MX2023007579A (es) Derivado de borato y usos del mismo.
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2023014131A (es) Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo.
MX2023008016A (es) Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
PH12021550323A1 (en) Dendrimer formulations
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2021014458A (es) Compuestos triciclicos.